Two Sigma Advisers’s Medifast MED Stock Holding History

Two Sigma Advisers’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-102,900	Closed	-$1.1M	–	1265
2025 Q4	$1.1M	Sell	102,900 -116,200	-53%	-$1.39M	﹤0.01%	1441
2025 Q3	$3M	Buy	219,100 +6,200	+3%	+$86.6K	0.01%	949
2025 Q2	$2.99M	Sell	212,900 -6,100	-3%	-$80.2K	0.01%	943
2025 Q1	$2.95M	Buy	219,000 +3,000	+1%	+$45.1K	0.01%	1002
2024 Q4	$3.81M	Buy	216,000 +99,900	+86%	+$1.85M	0.01%	829
2024 Q3	$2.22M	Buy	116,100 +1,600	+1%	+$30.8K	0.01%	1013
2024 Q2	$2.5M	Buy	114,500 +108,900	+1,945%	+$2.9M	0.01%	1074
2024 Q1	$215K	Sell	5,600 -4,500	-45%	-$218K	﹤0.01%	2191
2023 Q4	$679K	Hold	10,100	–	–	﹤0.01%	1801
2023 Q3	$756K	Sell	10,100 -100	-1%	-$8.87K	﹤0.01%	1640
2023 Q2	$940K	Buy	10,200 +6,900	+209%	+$614K	﹤0.01%	1564
2023 Q1	$342K	Buy	+3,300	New	+$366K	﹤0.01%	2092
2022 Q1	–	Sell	-4,600	Closed	-$963K	–	2839
2021 Q4	$963K	Sell	4,600 -2,400	-34%	-$496K	﹤0.01%	1573
2021 Q3	$1.35M	Sell	7,000 -82,900	-92%	-$20.4M	﹤0.01%	1470
2021 Q2	$25.4M	Sell	89,900 -20,600	-19%	-$5.58M	0.07%	283
2021 Q1	$23.4M	Sell	110,500 -34,100	-24%	-$8.16M	0.06%	326
2020 Q4	$28.4M	Buy	144,600 +35,600	+33%	+$6.29M	0.08%	263
2020 Q3	$17.9M	Buy	+109,000	New	+$17.9M	0.05%	347
2019 Q3	–	Sell	-47,500	Closed	-$6.09M	–	2328
2019 Q2	$6.09M	Sell	47,500 -6,968	-13%	-$968K	0.02%	750
2019 Q1	$6.95M	Buy	54,468 +5,200	+11%	+$660K	0.02%	727
2018 Q4	$6.16M	Buy	49,268 +2,595	+6%	+$444K	0.02%	731
2018 Q3	$10.3M	Buy	46,673 +3,000	+7%	+$608K	0.03%	571
2018 Q2	$7M	Sell	43,673 -15,900	-27%	-$2.03M	0.02%	708
2018 Q1	$5.57M	Buy	59,573 +30,300	+104%	+$2.26M	0.02%	805
2017 Q4	$2.04M	Sell	29,273 -3,262	-10%	-$216K	0.01%	1231
2017 Q3	$1.93M	Buy	32,535 +9,068	+39%	+$451K	0.01%	1217
2017 Q2	$973K	Sell	23,467 -5,306	-18%	-$231K	﹤0.01%	1531
2017 Q1	$1.28M	Sell	28,773 -3,897	-12%	-$168K	﹤0.01%	1465
2016 Q4	$1.36M	Sell	32,670 -24,599	-43%	-$991K	0.01%	1381
2016 Q3	$2.16M	Sell	57,269 -98,697	-63%	-$3.54M	0.01%	992
2016 Q2	$5.19M	Buy	155,966 +65,800	+73%	+$2.12M	0.03%	540
2016 Q1	$2.72M	Buy	90,166 +22,900	+34%	+$669K	0.02%	682
2015 Q4	$2.04M	Buy	67,266 +7,500	+13%	+$223K	0.01%	741
2015 Q3	$1.61M	Buy	59,766 +13,100	+28%	+$382K	0.01%	807
2015 Q2	$1.51M	Buy	46,666 +26,900	+136%	+$853K	0.01%	927
2015 Q1	$592K	Sell	19,766 -100	-0.5%	-$3.17K	﹤0.01%	1269
2014 Q4	$667K	Sell	19,866 -11,700	-37%	-$364K	0.01%	1423
2014 Q3	$1.04M	Sell	31,566 -10,251	-25%	-$315K	0.01%	1112
2014 Q2	$1.27M	Sell	41,817 -6,549	-14%	-$204K	0.01%	1038
2014 Q1	$1.41M	Buy	+48,366	New	+$1.3M	0.01%	953

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $403M AUM 43.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Two Sigma Advisers's MED Position: Q1 2026 in Review

Two Sigma Advisers sold out of Medifast (MED) in Q1 2026, closing a stake of 102,900 shares — an estimated $1.1M sold.

Two Sigma Advisers first reported a position in MED in Q1 2014 and held it in 40 quarters. The position peaked at $28.4M in Q4 2020. 111 funds tracked by Wall St. Rank hold MED as of Q1 2026.

Two Sigma Advisers reported no remaining Medifast position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 102,900 Medifast shares in Q1 2026, an estimated $1.1M.
Two Sigma Advisers first reported a position in Medifast in Q1 2014 and held it in 40 quarters.
Two Sigma Advisers's Medifast position peaked at $28.4M in Q4 2020.
111 funds tracked by Wall St. Rank held Medifast as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.